Abstract

Introduction

: Hepatitis C is one of the leading causes of chronic liver disease. The direct-acting-antivirals has revolutionized the chronic hepatitis C treatment. DAAs can achieve a sustained virological response rate >95% in different populations.

Area covered

: This review summarizes the pharmacokinetics, pharmacodynamics, efficacy, and safety of Elbasvir/Grazoprevir (EBR/GZR).

Expert opinion

: EBR/GZR is a combination of NS5A and NS3/4A inhibitors. The performance in the EBR/GZR combination’s safety and tolerability is appreciated in clinical treatment. EBR/GZR also has a higher barrier to resistance-associated substitutions. Based on clinical trials and real-world experience, elbasvir/grazoprevir is effective in the HCV GT1, 4 infections.

中文翻译：

---

Elbasvir和grazoprevir用于治疗丙型肝炎

摘要

介绍

：丙型肝炎是慢性肝病的主要原因之一。直接作用抗病毒药彻底改变了慢性丙型肝炎的治疗方法。在不同人群中，DAA可以实现持续的病毒学应答率> 95％。

覆盖面积

：这篇综述总结了Elbasvir / Grazoprevir（EBR / GZR）的药代动力学，药效学，功效和安全性。

专家意见

：EBR / GZR是NS5A和NS3 / 4A抑制剂的组合。EBR / GZR组合在安全性和耐受性方面的性能在临床治疗中受到赞赏。EBR / GZR对与耐药性相关的取代也有较高的障碍。根据临床试验和实际经验，elbasvir / grazoprevir可有效治疗HCV GT1 4感染。